• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Tozasertib

Tozasertib

Product ID T5996
Cas No. 639089-54-6
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $60.10 In stock
25 mg $105.30 In stock
100 mg $375.60 In stock
250 mg $721.20 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Tozasertib is an anticancer chemotherapeutic pan-aurora kinase (AurK) inhibitor that also inhibits FMS-like tyrosine kinase 3 (FLT3) and Abl. Tozasertib is currently in clinical trials as a potential treatment for acute lymphoblastic leukemia (ALL). In cellular models of cancer, tozasertib activates caspase-3 and PARP and decreases expression of HDAC, increasing apoptosis and inhibiting cell growth. In other cellular models, tozasertib inhibits cell proliferation and metastasis by blocking downstream ERK signaling and downregulating cdc25c and cyclin B. This compound also decreases tumor growth in an in vivo model of prostate cancer.

Product Info

Cas No.

639089-54-6

Purity

≥98%

Formula

C23H28N8OS

Formula Wt.

464.59

Chemical Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide

IUPAC Name

N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino] pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide

Synonym

VX680, MK0457

Melting Point

245-260°C

Solubility

DMSO at 100 mg/mL

Appearance

White to pale yellow powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

T5996 MSDS PDF

Info Sheet

T5996 Info Sheet PDF

References

Okabe S, Tauchi T, Tanaka Y, et al. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells. Cancer Cell Int. 2013 Apr 4;13(1):32. PMID: 23556431.

Li Y, Zhou W, Wei L, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol. 2012 Dec;41(6):2139-49. PMID: 23007526.

Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia. 2013 Jan;27(1):113-7. PMID: 22772060.

Jeet V, Russell PJ, Verma ND, et al. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets. 2012 Feb;12(2):144-63. PMID: 22229247.

Salah E, Ugochukwu E, Barr AJ, et al. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011 Apr 14;54(7):2359-67. PMID: 21417343.

Oliveira TM, Ahmad R, Engh RA. VX680 binding in Aurora A: π-π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop. J Phys Chem A. 2011 Apr 28;115(16):3895-904. PMID: 21306143.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E6993

    Erythromycin Resistance Peptide MRLFV

    Peptide, confers resistance against macrolide a...

    ≥95%
  • D5897

    Doxycycline Hyclate

    Tetracycline; protein translation inhibitor, MMP i...
    ≥97%
  • L960010

    LY-3200882

    TGF-β1 inhibitor.

    ≥98%
  • C9615

    Cyclosporin B

    Cyclic peptide; calcineurin inhibitor.

    ≥95%
  • V3276

    Vitamin E, Natural

    Antioxidant.

    ≥97%
  • A6368

    Aprepitant

    NK1 antagonist.

    ≥98%
  • V3325

    Virginiamycin M1

    Macrolide antibiotic; peptidyl transferase inhi...

    ≥97%
  • A7604

    ATB 346

    NSAID; COX inhibitor and HS-releasing agent.

    ≥99%
  • D3330

    Dihydrotanshinone

    Found in Salvia; fatty acid synthase and AChE i...

    ≥90%
  • E2003

    Efavirenz

    Non-nucleoside RT inhibitor.

    ≥99%
  • C4457

    Clomipramine Hydrochloride

    FIASMA, mAChR, 5-HT2/3/6/7, α1/2-adrenergic an...

    ≥98%
  • T0099

    10-Deacetylbaccatin-III

    Diterpene found in Taxus.

    ≥98%
  • K1678

    Ketanserin

    5-HT2A antagonist, potential α1-adrenergic ant...

    ≥97%
  • N5072

    NMS-1286937

    PLK1 inhibitor.

    ≥98%
  • M7528

    α-Melanocyte Stimulating Hormone

    Endogenous peptide hormone derived from POMC, i...

    ≥98%
  • D0006

    Dacomitinib Monohydrate

    EGFR inhibitor.

    ≥99%
  • I6932

    Irinotecan

    Camptothecin analog; topoisomerase I inhibitor,...

    ≥98%
  • N3278

    7-Nitroindazole

    nNOS inhibitor.

    ≥98%
  • E537332

    Enniatin A

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • T0091

    7-(Triethylsilyl)-10-deacetylbaccatin III

    Taxol derivative.

    ≥97%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only